Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

NCT00703326 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1144

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: ramucirumab (IMC-1121B)
DRUG: docetaxel
OTHER: Placebo

Sponsor

Eli Lilly and Company